08:30 - 09:00 EDT
Jeanne Timmins Foyer, The Neuro
Preliminary Program
* All times are based on Canada/Eastern EST.
08:30
Canada/Eastern
09:00
Canada/Eastern
10:00
Canada/Eastern
10:00 - 11:15 EDT
Jeanne Timmins Amphitheatre, The Neuro
Session 1: Human Biomarkers & Imaging
· PET ligands (VAChT/AChE/M1-M4): kinetics and quantification · Multimodal fusion: MRI/EEG/MEG/FDG & plasma/CSF markers · Longitudinal cohorts & progression modeling: staging and heterogeneity · Panel (15): Decision-ready biomarkers
11:30
Canada/Eastern
11:30 - 12:45 EDT
Jeanne Timmins Amphitheatre, The Neuro
Session 2: Non-human Models & Cross-Species Translation
· Mouse & NHP disease models focused on cholinergic mechanisms: basal-forebrain/striatal circuits, receptor-specific perturbations · Glial-cholinergic interactions in vulnerability and repair: astrocytes/microglia shaping circuit outcomes · Aligning endpoints across species: behavior, imaging, and electrophysiology that scale to human biomarkers · Panel (15): What truly translates? Building cross-species bridges
14:15
Canada/Eastern
14:15 - 15:30 EDT
Jeanne Timmins Amphitheatre, The Neuro
Session 3: Therapeutic Discovery & Pharmacology
· Selective & allosteric modulators: M1-M4, α7/α4β2; PAMs/ago-PAMs; biased signaling · Target product profiles: CNS penetration, PK/PD, tolerability & peripheral sparing · Safety & translatability: AEs, cholinergic burden, off-target mitigation, DDIs · Panel (15): From lead to label: de-risking cholinergic therapies
15:45
Canada/Eastern
